NO169048C - Fremgangsmaate for fremstilling av en makromolekylaer baererfylt med en lipofil biologisk aktiv substans - Google Patents

Fremgangsmaate for fremstilling av en makromolekylaer baererfylt med en lipofil biologisk aktiv substans

Info

Publication number
NO169048C
NO169048C NO870545A NO870545A NO169048C NO 169048 C NO169048 C NO 169048C NO 870545 A NO870545 A NO 870545A NO 870545 A NO870545 A NO 870545A NO 169048 C NO169048 C NO 169048C
Authority
NO
Norway
Prior art keywords
ldl
active substance
pct
biologically active
lyophilized
Prior art date
Application number
NO870545A
Other languages
English (en)
Norwegian (no)
Other versions
NO870545D0 (no
NO870545L (no
NO169048B (no
Inventor
Michele Masquelier
Curt Peterson
Mikael Ros
Mats Rudling
Sigurd Vitols
Original Assignee
Oncholab Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Oncholab Ab filed Critical Oncholab Ab
Publication of NO870545D0 publication Critical patent/NO870545D0/no
Publication of NO870545L publication Critical patent/NO870545L/no
Publication of NO169048B publication Critical patent/NO169048B/no
Publication of NO169048C publication Critical patent/NO169048C/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
    • A61K9/1275—Lipoproteins or protein-free species thereof, e.g. chylomicrons; Artificial high-density lipoproteins [HDL], low-density lipoproteins [LDL] or very-low-density lipoproteins [VLDL]; Precursors thereof

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Dispersion Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Immobilizing And Processing Of Enzymes And Microorganisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Macromonomer-Based Addition Polymer (AREA)
  • Agricultural Chemicals And Associated Chemicals (AREA)
NO870545A 1985-06-17 1987-02-11 Fremgangsmaate for fremstilling av en makromolekylaer baererfylt med en lipofil biologisk aktiv substans NO169048C (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
SE8502998A SE456136B (sv) 1985-06-17 1985-06-17 Forfarande for framstellning av en med ett lipofilt biologiskt aktivt emne bemengd berare pa basis av rekonstituerat ldl (lagdensitetslipoprotein)
PCT/SE1986/000291 WO1986007540A1 (en) 1985-06-17 1986-06-17 Method for the preparation of a macromolecular carrier loaded with a biologically active substance, product thus obtained and use thereof

Publications (4)

Publication Number Publication Date
NO870545D0 NO870545D0 (no) 1987-02-11
NO870545L NO870545L (no) 1987-02-11
NO169048B NO169048B (no) 1992-01-27
NO169048C true NO169048C (no) 1992-05-06

Family

ID=20360603

Family Applications (1)

Application Number Title Priority Date Filing Date
NO870545A NO169048C (no) 1985-06-17 1987-02-11 Fremgangsmaate for fremstilling av en makromolekylaer baererfylt med en lipofil biologisk aktiv substans

Country Status (11)

Country Link
US (1) US4868158A (da)
EP (1) EP0229100B1 (da)
JP (1) JPS62502549A (da)
AT (1) ATE67412T1 (da)
AU (1) AU583402B2 (da)
DE (1) DE3681578D1 (da)
DK (1) DK168785B1 (da)
FI (1) FI86802C (da)
NO (1) NO169048C (da)
SE (1) SE456136B (da)
WO (1) WO1986007540A1 (da)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2609399A1 (fr) * 1987-01-13 1988-07-15 Ire Celltarg Sa Procede d'incorporation d'un ou plusieurs principes actifs lipophiles dans des lipoproteines, lipoproteines obtenues et composition pharmaceutique les contenant
FR2664500B1 (fr) * 1990-07-13 1994-10-28 Lille Ii Universite Droit Sant Procede de preparation d'une lipoproteine modifiee par incorporation d'une substance active lipophile, lipoproteine modifiee ainsi obtenue et composition pharmaceutique ou cosmetique la contenant.
EP0611306B1 (en) * 1991-11-08 1998-07-08 Somatogen, Inc. Hemoglobins as drug delivery agents
WO1993020800A1 (en) * 1992-04-08 1993-10-28 Paavo Kai Johannes Kinnunen Composition for therapeutic or diagnostic use, process for its preparation and its use
AU690592B2 (en) * 1993-11-08 1998-04-30 Peptide Delivery Systems Pty Ltd Labelled diagnostic compositions and methods of their use
US5756067A (en) * 1993-11-08 1998-05-26 Peptide Delivery Systems Pty Ltd Labelled diagnostic compositions and method of their use
US5652339A (en) * 1993-12-31 1997-07-29 Rotkreuzstiftung Zentrallaboratorium Method of producing reconstituted lipoproteins
CA2259179C (en) * 1996-07-03 2008-09-23 University Of Pittsburgh Emulsion formulations for hydrophilic active agents
AUPP032097A0 (en) * 1997-11-11 1997-12-04 Peptide Delivery Systems Pty Ltd Improved labelled diagnostic compositions and methods of their use
US6514523B1 (en) 2000-02-14 2003-02-04 Ottawa Heart Institute Research Corporation Carrier particles for drug delivery and process for preparation
US20090110739A1 (en) * 2007-05-15 2009-04-30 University Of North Texas Health Science Center At Forth Worth Targeted cancer chemotherapy using synthetic nanoparticles
US8734853B2 (en) 2008-11-17 2014-05-27 University Of North Texas Health Science Center At Fort Worth HDL particles for delivery of nucleic acids
US20160346219A1 (en) 2015-06-01 2016-12-01 Autotelic Llc Phospholipid-coated therapeutic agent nanoparticles and related methods
US12194157B2 (en) 2020-04-09 2025-01-14 Finncure Oy Carrier for targeted delivery to a host
FI20215508A1 (en) 2020-04-09 2021-10-10 Niemelae Erik Johan Mimetic nanoparticles to prevent the spread of new coronaviruses and reduce the rate of infection

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ180199A (en) * 1976-03-04 1978-11-13 New Zealand Dev Finance Method of testing for the presence of elevated plasma liprotein concentration
US4186192A (en) * 1978-12-18 1980-01-29 Cutter Laboratories, Inc. Stabilized immune serum globulin
US4440679A (en) * 1980-03-05 1984-04-03 Cutter Laboratories, Inc. Pasteurized therapeutically active protein compositions
US4356117A (en) * 1980-10-23 1982-10-26 U.S. Govt., Dept. Of Health & Human Services Chemical modifications of proteins which induce new receptor specificities and therefore elicit new effects in cells
JPS5967228A (ja) * 1982-10-07 1984-04-16 Green Cross Corp:The 寒冷不溶性グロブリンの凍結乾燥方法
US4478829A (en) * 1983-04-28 1984-10-23 Armour Pharmaceutical Company Pharmaceutical preparation containing purified fibronectin
NZ208241A (en) * 1984-05-22 1987-09-30 John Stephen Ayers Purification of blood plasma or serum: selective removal of (very) low density lipoproteins (ldl and vldl)
AU6408586A (en) * 1985-10-03 1987-04-24 Biotechnology Research Partners Limited Novel lipoprotein-based drug-delivery systems

Also Published As

Publication number Publication date
SE8502998L (sv) 1986-12-18
NO870545D0 (no) 1987-02-11
FI870644A0 (fi) 1987-02-16
WO1986007540A1 (en) 1986-12-31
SE8502998D0 (sv) 1985-06-17
NO870545L (no) 1987-02-11
DK77787A (da) 1987-02-16
DE3681578D1 (de) 1991-10-24
FI86802C (fi) 1992-10-26
DK168785B1 (da) 1994-06-13
EP0229100B1 (en) 1991-09-18
ATE67412T1 (de) 1991-10-15
JPS62502549A (ja) 1987-10-01
FI86802B (fi) 1992-07-15
AU5996886A (en) 1987-01-13
AU583402B2 (en) 1989-04-27
US4868158A (en) 1989-09-19
EP0229100A1 (en) 1987-07-22
SE456136B (sv) 1988-09-12
FI870644A7 (fi) 1987-02-16
NO169048B (no) 1992-01-27
DK77787D0 (da) 1987-02-16
JPH0586935B2 (da) 1993-12-14

Similar Documents

Publication Publication Date Title
NO169048C (no) Fremgangsmaate for fremstilling av en makromolekylaer baererfylt med en lipofil biologisk aktiv substans
Kandutsch et al. Studies on a substance that promotes tumor homograft survival (the" enhancing substance"): Its distribution and some properties
Christensen et al. Comparative ability of seminiferous tubules and interstitial tissue of rat testes to synthesize androgens from progesterone-4-14C in vitro
CRONIN et al. Human pancreatic tumor growth hormone (GH)-releasing factor and cyclic adenosine 3′, 5′-monophosphate evoke GH release from anterior pituitary cells: the effects of pertussis toxin, cholera toxin, forskolin, and cycloheximide
Lichtenberger et al. Importance of amino acid uptake and decarboxylation in gastrin release from isolated G cells
CHAKRAVARTY et al. Mechanism of tho Release by Componnd 48/80 of Histamine and of a Lipid‐Soluble Smooth Muscle Stimulating Principle (“SRS”)
DK0652754T3 (da) Lægemidler til topisk påføring af kønssteroider til behandling af tørt øje-syndrom samt fremgangsmåder til fremstilling og påføring deraf
CZ292684B6 (cs) Použití extraktů rostlin Iris a Cimicifuga racemosa a tektorigeninu jako estrogenního organoselektivního léčiva bez uterotropního účinku
Haller et al. Alcoholic rhabdomyolysis: an experimental model in the rat
Stachel et al. Zilpaterol—a new focus of concern in residue analysis
White Effects of steroids on aspects of the metabolism and functions of the lymphocyte: a hypothesis of the cellular mechanisms in antibody formation and related immune phenomena
SE8703064D0 (sv) Method for isolating active enzyme preparations from animal tissues
FI912687A0 (fi) Araban fraon vilken foergreningar avlaegsnats och dess anvaendning som fettersaettare.
Strang et al. Extraction, purification and turnover of rat brain glycogen
Wigglesworth Histological staining of lipids for the light and electron microscope
Kempen et al. Rat pancreatic adenylate cyclase: IV. Effect of hormones and other agents on cyclic AMP level and enzyme release
WENDEL et al. A cytochemical approach to the lipid composition of mitochondrial matrix granules in brown adipose tissue and liver
Chulavatnatol et al. Lack of effect of α-chlorohydrin on the ATP content of rat, mouse and human spermatozoa
Vandenberg et al. Adenyl cyclase in the haemocytes of the American cockroach
KR890701596A (ko) 알카로이드 추출
Dalterio et al. Acute Δ9-tetrahydrocannabinol exposure: effects of hypothalamic-pituitary-testicular activity in mice
BR9205264A (pt) Processo para a obtencao de composicoes e/ou substancias que tem uma atividade anti-neoplastica,substancia e composicoes,preparacao farmaceutica e uso dos componentes que podem ser obtidos por meio processo
Rosenfeld et al. Effects of sugars on the anthelmintic activity of kalafungin
Bicknell et al. Mechanism of action of somatostatin: growth-hormone release [45Ca] calcium ion efflux and cyclic nucleotide metabolism of bovine anterior-pituitary slices in the presence of prostaglandin E2 and 1-methyl-3-isobutylxanthine
Schurgers et al. Absorption of etoposide (VP-16-213) from the small intestine of the rat. The potential role of mucus as an absorption rate limiting barrier